Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Molecular Cancer Therapeutics|March 16, 2013
The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growthEdward B Garon, Richard S Finn, Habib Hamidi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
ERCC5 is a novel biomarker of ovarian cancer prognosisChristine S Walsh, Seishi Ogawa, Hisae Karahashi, et al.
Gynecologic Oncology|March 27, 2016
Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signaturesBoris Winterhoff, Habib Hamidi, Chen Wang, et al.
The Journal of Clinical Investigation|April 26, 2014
Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearanceRachel A Davidowitz, Laura M Selfors, Marcin P Iwanicki, et al.
Journal of the National Cancer Institute|October 2, 2014
Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancerGottfried E Konecny, Chen Wang, Habib Hamidi, et al.
Molecular Carcinogenesis|September 23, 2003
Novel consensus DNA-binding sequence for BRCA1 protein complexesP LouAnn Cable, Cindy A Wilson, Frank J Calzone, et al.
Molecular Cancer Therapeutics|June 5, 2013
Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancerMaike Ihnen, Christine zu Eulenburg, Teodora Kolarova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2011
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancerGottfried E Konecny, Boris Winterhoff, Teodora Kolarova, et al.
Nature Communications|November 18, 2020
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)Sara A Hurvitz, Jennifer L Caswell-Jin, Katherine L McNamara, et al.
Cancer Research|March 11, 2010
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)Jonathan R Dry, Sandra Pavey, Christine A Pratilas, et al.
Pageof 3